Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice
- 8 February 2019
- journal article
- research article
- Published by Springer Nature in Drugs & Aging
- Vol. 36 (4) , 379-385
Abstract
Older patients with metastatic castration-resistant prostate cancer (mCRPC) may be more prone to chemotherapy-induced hematological toxicity, but tailored docetaxel dosing guidelines in older patients are lacking because of conflicting data.Keywords
This publication has 26 references indexed in Scilit:
- Analysis of docetaxel therapy in elderly (⩾70years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate StudyEuropean Journal of Cancer, 2013
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate CancerJournal of Clinical Oncology, 2010
- Pharmacokinetics and drug metabolism in the elderlyDrug Metabolism Reviews, 2009
- Polypharmacy in elderly patientsThe American Journal of Geriatric Pharmacotherapy, 2007
- Clinical pharmacodynamic factors in docetaxel toxicityBritish Journal of Cancer, 2007
- Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the ElderlyJournal of Clinical Oncology, 2005
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Weekly Docetaxel in Elderly Patients with Prostate Cancer: Efficacy and Toxicity in Patients Aged ≥ 70 Years Compared with Patients Aged < 70 YearsClinical Prostate Cancer, 2003
- AnnexUniversity of Toronto Law Journal, 1971